{"title":"继发于 SGLT2i 的急性胰腺炎 - 一个越来越常见的问题。","authors":"Alba Cortés-Gonzalez, Belén Bernad-Cabredo","doi":"10.17235/reed.2024.10789/2024","DOIUrl":null,"url":null,"abstract":"<p><p>Acute pancreatitis is an uncommon adverse effect of sodium-glucose linked transporter 2 inhibitors (SGLT2is). Their use has notably increased in recent years, hence clinical suspicion is key in patients recently started on these drugs. We report the case of an 83-year-old male patient who was admitted for a first acute pancreatitis episode of unclear etiology that eventually was attributed to dapaglifozin, a SGLT2i in widespread use.</p>","PeriodicalId":21342,"journal":{"name":"Revista Espanola De Enfermedades Digestivas","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acute pancreatitis secondary to SGLT2i - An increasingly common problem.\",\"authors\":\"Alba Cortés-Gonzalez, Belén Bernad-Cabredo\",\"doi\":\"10.17235/reed.2024.10789/2024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Acute pancreatitis is an uncommon adverse effect of sodium-glucose linked transporter 2 inhibitors (SGLT2is). Their use has notably increased in recent years, hence clinical suspicion is key in patients recently started on these drugs. We report the case of an 83-year-old male patient who was admitted for a first acute pancreatitis episode of unclear etiology that eventually was attributed to dapaglifozin, a SGLT2i in widespread use.</p>\",\"PeriodicalId\":21342,\"journal\":{\"name\":\"Revista Espanola De Enfermedades Digestivas\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola De Enfermedades Digestivas\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17235/reed.2024.10789/2024\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Enfermedades Digestivas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17235/reed.2024.10789/2024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Acute pancreatitis secondary to SGLT2i - An increasingly common problem.
Acute pancreatitis is an uncommon adverse effect of sodium-glucose linked transporter 2 inhibitors (SGLT2is). Their use has notably increased in recent years, hence clinical suspicion is key in patients recently started on these drugs. We report the case of an 83-year-old male patient who was admitted for a first acute pancreatitis episode of unclear etiology that eventually was attributed to dapaglifozin, a SGLT2i in widespread use.
期刊介绍：
La Revista Española de Enfermedades Digestivas, Órgano Oficial de la Sociedad Española de Patología Digestiva (SEPD), Sociedad Española de Endoscopia Digestiva (SEED) y Asociación Española de Ecografía Digestiva (AEED), publica artículos originales, editoriales, revisiones, casos clínicos, cartas al director, imágenes en patología digestiva, y otros artículos especiales sobre todos los aspectos relativos a las enfermedades digestivas.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
